Literature DB >> 2833568

Murine IgG subclass responses to herpes simplex virus type 1 and polypeptides.

R R McKendall1, W Woo.   

Abstract

The antibody response to herpes simplex virus (HSV) is complex and involves antibody to at least 33 virus-induced polypeptides. Serum IgG contains four isotypes in mice and it is known that the isotypes differ in their biological functions and that individual antigenic proteins may preferentially elicit restricted isotype responses. We therefore examined the anti-polypeptide isotypes induced in immune mouse serum. By ELISA, we found that the total serum virus-specific antibody activity was 51% IgG1, 39% IgG2a, 11% IgG2b and 1% IgG3 in immune ICR strain mice and 51%, 45%, 4% and 0.4% respectively in strain BALB/c mouse immune serum. These proportions are significantly different from those reported for other virus infections. Sepharose-Protein A affinity-purified isotypes were also studied and showed IgG1 greater than IgG2a greater than or equal to IgG2b much greater than IgG3 activity per microgram of isotype, indicating that competition between isotypes present in high concentrations did not significantly alter the results. Immunoblotting studies of the purified isotypes showed that the major immunogenic HSV-1 proteins (VP155, gC, gB, pgB, gD and nucleocapsid proteins 42K and 44K) induced all isotypes. However, the isotype responses were not uniform among the glycoproteins and some other proteins. In addition neutralization assays of the purified isotypes indicated that IgG2a and IgG2b had significantly greater neutralizing capacity than IgG1, suggesting that less of the IgG1 was directed against neutralizing virion epitopes. These data are discussed with respect to the biological implications in host defence.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833568     DOI: 10.1099/0022-1317-69-4-847

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants.

Authors:  Dominique Markine-Goriaynoff; Jean-Paul Coutelier
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Use of pre-S protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection.

Authors:  Jung Sun Yum; Byung Cheol Ahn; Hyun Jin Jo; Dong Yeon Kim; Ki Hyun Kim; Hyo Sun Kim; Young Chul Sung; Jaeseung Yoon; John Morrey; Hong Mo Moon
Journal:  Clin Vaccine Immunol       Date:  2011-12-07

3.  Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.

Authors:  I M Fernández; A Snijders; B J Benaissa-Trouw; M Harmsen; H Snippe; C A Kraaijeveld
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

4.  An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.

Authors:  Mojca Skoberne; Rhonda Cardin; Alexander Lee; Ana Kazimirova; Veronica Zielinski; Danielle Garvie; Amy Lundberg; Shane Larson; Fernando J Bravo; David I Bernstein; Jessica B Flechtner; Deborah Long
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

5.  Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

Authors:  Christopher S Morello; Kimberly A Kraynyak; Michael S Levinson; Zhijiang Chen; Kuo-Fen Lee; Deborah H Spector
Journal:  Vaccine       Date:  2012-09-01       Impact factor: 3.641

6.  Toll-like Receptor 1/2 Agonist Pam3CSK4 Suppresses Lipopolysaccharide-driven IgG1 Production while Enhancing IgG2a Production by B Cells.

Authors:  Sang-Hoon Lee; Seok-Rae Park
Journal:  Immune Netw       Date:  2018-02-20       Impact factor: 6.303

7.  Involvement of STAT4 in IgG subtype switching and ocular HSV-1 replication in mice.

Authors:  Sariah J Allen; Kevin R Mott; Homayon Ghiasi
Journal:  Mol Vis       Date:  2010-01-26       Impact factor: 2.367

8.  The Nod2 Agonist Muramyl Dipeptide Cooperates with the TLR4 Agonist Lipopolysaccharide to Enhance IgG2b Production in Mouse B Cells.

Authors:  Sang-Hoon Lee; Jong-Hwan Park; Seok-Rae Park
Journal:  J Immunol Res       Date:  2019-11-26       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.